The mRNA ratio of (MCL-1 + Bfl-1)/BCL-2 provided a prognostic index marker for the sensitivity of CLL cells to ABT-737, the ratio being lower in the sensitive group as compared to its resistant variants43. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.